首页> 外文期刊>Bone marrow transplantation >Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan.
【24h】

Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan.

机译:次要组织相容性抗原的不匹配会导致移植物抗白血病效应,而不是导致急性GVHD,从而导致在日本进行HLA相同的干细胞移植后能够长期存活。

获取原文
获取原文并翻译 | 示例
       

摘要

We determined the alleles of five polymorphic molecules including HA-1 and four adhesion molecules for 106 patients transplanted with HLA-identical stem cell grafts and investigated the association of mismatches as correlates of relapse and graft-versus-host disease (GVHD). All 106 recipients underwent stem cell transplantation (SCT) after myeloablative conditioning between 1985 and 2002. Risk status of disease at SCT was standard (n=63) and high (n=42). After SCT, 36, 49 and 33 developed acute GVHD, chronic GVHD and relapsed, respectively. Our patients relapsed at rates of 16.7 and 38.6% with one or more and without incompatibilities (P=0.013). The relapse rates of patients with CD62L, CD31 codon 563, CD31 codon 125, HA-1 and CD49b incompatibilities were 5.9, 11.8, 15.4, 16.0 and 33.3%, respectively. The frequency of acute GVHD did not differ regardless of incompatibilities. In standard-risk group, the accumulated relapse rates of 19 and 44 patients with and without minor histocompatibility antigen incompatibility were 22% and unexpectedly 66%, respectively (P=0.02). The probability of 12-year survival was 88% in the former and 66% in the latter patients (P=0.03). Our data suggest that incompatibility of CD62L, CD31 codon 563 and CD31 codon 125 contributes to a graft-versus-leukemia effect rather than to GVHD, resulting in prolonged survival after HLA-identical SCT.
机译:我们确定了106例接受HLA相同干细胞移植的患者的5个多态性分子(包括HA-1和4个粘附分子)的等位基因,并研究了错配与复发和移植物抗宿主病(GVHD)相关的关联。在1985年至2002年之间,所有106位接受者在进行清髓处理后均接受了干细胞移植(SCT)。SCT的疾病风险状态为标准(n = 63)和高(n = 42)。 SCT后,分别有36、49和33位患者发展为急性GVHD,慢性GVHD和复发。我们的患者复发率为16.7和38.6%,其中一种或多种复发且无不相容性(P = 0.013)。 CD62L,CD31密码子563,CD31密码子125,HA-1和CD49b不相容的患者的复发率分别为5.9%,11.8%,15.4%,16.0%和33.3%。不管是否存在相容性,急性GVHD的发生频率均没有差异。在标准风险组中,有和没有组织相容性抗原不相容性的19例和44例患者的累积复发率分别为22%和出乎意料的66%(P = 0.02)。前者12年生存的可能性为88%,后者为66%(P = 0.03)。我们的数据表明,CD62L,CD31密码子563和CD31密码子125的不相容性会导致移植物抗白血病效应,而不是GVHD,从而导致在HLA相同的SCT后存活时间延长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号